42 related articles for article (PubMed ID: 34042032)
1. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells.
Wilmore S; Rogers-Broadway KR; Taylor J; Lemm E; Fell R; Stevenson FK; Forconi F; Steele AJ; Coldwell M; Packham G; Yeomans A
Cell Mol Life Sci; 2021 Sep; 78(17-18):6337-6349. PubMed ID: 34398253
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A.
Chen M; Asanuma M; Takahashi M; Shichino Y; Mito M; Fujiwara K; Saito H; Floor SN; Ingolia NT; Sodeoka M; Dodo K; Ito T; Iwasaki S
Cell Chem Biol; 2021 Apr; 28(4):475-486.e8. PubMed ID: 33296667
[TBL] [Abstract][Full Text] [Related]
3. Broad anti-pathogen potential of DEAD box RNA helicase eIF4A-targeting rocaglates.
Obermann W; Azri MFD; Konopka L; Schmidt N; Magari F; Sherman J; Silva LMR; Hermosilla C; Ludewig AH; Houhou H; Haeberlein S; Luo MY; Häcker I; Schetelig MF; Grevelding CG; Schroeder FC; Lau GSK; Taubert A; Rodriguez A; Heine A; Yeo TC; Grünweller A; Taroncher-Oldenburg G
Sci Rep; 2023 Jun; 13(1):9297. PubMed ID: 37291191
[TBL] [Abstract][Full Text] [Related]
4. Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.
Kayastha F; Herrington NB; Kapadia B; Roychowdhury A; Nanaji N; Kellogg GE; Gartenhaus RB
Mol Med; 2022 Sep; 28(1):101. PubMed ID: 36058921
[TBL] [Abstract][Full Text] [Related]
5. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer.
Wolfe AL; Singh K; Zhong Y; Drewe P; Rajasekhar VK; Sanghvi VR; Mavrakis KJ; Jiang M; Roderick JE; Van der Meulen J; Schatz JH; Rodrigo CM; Zhao C; Rondou P; de Stanchina E; Teruya-Feldstein J; Kelliher MA; Speleman F; Porco JA; Pelletier J; Rätsch G; Wendel HG
Nature; 2014 Sep; 513(7516):65-70. PubMed ID: 25079319
[TBL] [Abstract][Full Text] [Related]
6. A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer.
Cencic R; Im YK; Naineni SK; Moustafa-Kamal M; Jovanovic P; Sabourin V; Annis MG; Robert F; Schmeing TM; Koromilas A; Paquet M; Teodoro JG; Huang S; Siegel PM; Topisirovic I; Ursini-Siegel J; Pelletier J
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2318093121. PubMed ID: 38232291
[TBL] [Abstract][Full Text] [Related]
7. Intercepted Retro-Nazarov Reaction: Syntheses of Amidino-Rocaglate Derivatives and Their Biological Evaluation as eIF4A Inhibitors.
Zhang W; Chu J; Cyr AM; Yueh H; Brown LE; Wang TT; Pelletier J; Porco JA
J Am Chem Soc; 2019 Aug; 141(32):12891-12900. PubMed ID: 31310112
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous Sequences of Brain Cytoplasmic 200 RNA Formed by Multiple Adenine Nucleotide Insertions.
Shin H; Lee J; Kim Y; Jang S; Kim M; Lee Y
Mol Cells; 2019 Jun; 42(6):495-500. PubMed ID: 31250622
[TBL] [Abstract][Full Text] [Related]
9. eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.
Boyer JA; Sharma M; Dorso MA; Mai N; Amor C; Reiter JM; Kannan R; Gadal S; Xu J; Miele M; Li Z; Chen X; Chang Q; Pareja F; Worland S; Warner D; Sperry S; Chiang GG; Thompson PA; Yang G; Ouerfelli O; de Stanchina E; Wendel HG; Rosen EY; Chandarlapaty S; Rosen N
bioRxiv; 2024 May; ():. PubMed ID: 38766126
[TBL] [Abstract][Full Text] [Related]
10. Eukaryotic translation initiation factor 4A1 in the pathogenesis and treatment of cancers.
Huang J; Zhang L; Yang R; Yao L; Gou J; Cao D; Pan Z; Li D; Pan Y; Zhang W
Front Mol Biosci; 2023; 10():1289650. PubMed ID: 38028556
[TBL] [Abstract][Full Text] [Related]
11. eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer's vulnerability.
Casacuberta-Serra S; Gonzalez-Larreategui I; Soucek L
Transl Lung Cancer Res; 2023 Dec; 12(12):2570-2575. PubMed ID: 38205207
[No Abstract] [Full Text] [Related]
12. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
Nishida Y; Zhao R; Heese LE; Akiyama H; Patel S; Jaeger AM; Jacamo RO; Kojima K; Ma MCJ; Ruvolo VR; Chachad D; Devine W; Lindquist S; Davis RE; Porco JA; Whitesell L; Andreeff M; Ishizawa J
Leukemia; 2021 Sep; 35(9):2469-2481. PubMed ID: 34127794
[TBL] [Abstract][Full Text] [Related]
13. Small-Molecule Inhibitors Targeting eIF4A in Leukemia.
Jia X; Zhou H
Curr Protein Pept Sci; 2021; 22(7):559-566. PubMed ID: 34042032
[TBL] [Abstract][Full Text] [Related]
14. ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A.
Tillotson J; Kedzior M; Guimarães L; Ross AB; Peters TL; Ambrose AJ; Schmidlin CJ; Zhang DD; Costa-Lotufo LV; Rodríguez AD; Schatz JH; Chapman E
Bioorg Med Chem Lett; 2017 Sep; 27(17):4082-4085. PubMed ID: 28757063
[TBL] [Abstract][Full Text] [Related]
15. RNA aptamers to initiation factor 4A helicase hinder cap-dependent translation by blocking ATP hydrolysis.
Oguro A; Ohtsu T; Svitkin YV; Sonenberg N; Nakamura Y
RNA; 2003 Apr; 9(4):394-407. PubMed ID: 12649492
[TBL] [Abstract][Full Text] [Related]
16. eIF4B stimulates eIF4A ATPase and unwinding activities by direct interaction through its 7-repeats region.
Andreou AZ; Harms U; Klostermeier D
RNA Biol; 2017 Jan; 14(1):113-123. PubMed ID: 27858515
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting of the DEAD-box RNA helicase eukaryotic initiation factor (eIF) 4A by natural products.
Shen L; Pelletier J
Nat Prod Rep; 2020 May; 37(5):609-616. PubMed ID: 31782447
[TBL] [Abstract][Full Text] [Related]
18. The DEAD-box helicase eIF4A: paradigm or the odd one out?
Andreou AZ; Klostermeier D
RNA Biol; 2013 Jan; 10(1):19-32. PubMed ID: 22995829
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
